Oc­u­lar cuts staff in wake of FDA slap­down; Bio­gen re­cruits Pfiz­er vet; X4 inks dis­cov­ery deal with Yale

→ Just days af­ter its bid to sal­vage its sec­ond ap­pli­ca­tion for the drug/de­vice eye ther­a­py Dex­ten­za failed with an­oth­er slap­down by reg­u­la­tors, the Oc­u­lar Ther­a­peu­tics $OCUL is cut­ting staff and shak­ing up the C suite. The biotech said that Antony Mat­tes­sich has as­sumed the role of CEO while for­mer CEO Amar Sawh­ney has tran­si­tioned to ex­ec­u­tive chair­man. The biotech al­so re­duced its head count by 19%.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.